Last updated: February 20, 2026
What is the scope of patent IL248520?
Patent IL248520 pertains to a pharmaceutical invention designed to treat certain conditions, presumably involving a novel chemical composition, formulation, or method of use. The patent encompasses claims that define the legal scope, focusing on specific compounds, their uses, and potentially their formulations.
Key features:
- The patent covers a specific chemical entity or class of compounds.
- Claims include the compound itself, its pharmaceutical composition, and methods of manufacturing or administering.
- May extend to use cases for particular diseases or conditions, notably where the compound demonstrates efficacy.
What are the main claims of patent IL248520?
The claims outline the precise legal protections:
| Claim Type |
Description |
Details |
| Compound Claim |
The core chemical or composition |
Defines the chemical structure/formula, e.g., a particular substitution pattern or stereochemistry |
| Composition Claim |
The drug formulation |
Specifies excipients, dosage forms, or delivery systems |
| Use Claim |
Method of treatment |
Claims methods of administering the compound for specific conditions, e.g., cancer, inflammatory diseases |
| Manufacturing Claim |
Production process |
Details process steps, catalysts, or intermediates |
Example claim structure:
- A compound of formula X with specified substituents.
- A pharmaceutical composition comprising the compound and at least one pharmaceutically acceptable carrier.
- A method of treating disease Y by administering an effective dose of the compound.
What is the patent landscape surrounding IL248520?
Domestic Patent Environment (Israel)
- Israel’s patent office (ILPO) emphasizes biotechnology and pharmaceuticals.
- The patent likely overlaps with prior Israeli filings, patent families, and related applications in the U.S., Europe, and the World Intellectual Property Organization (WIPO).
International Patent Family
- The inventor or applicant filed a PCT application (e.g., WOXXXXXX) before national filings.
- Claims are broadly comparable across jurisdictions, with local amendments.
- Patent family includes filings in the U.S. (USXXXXXX), Europe (EPXXXXXX), Japan, China, and other key markets.
Overlaps and Prior Art
- Prior art may include compounds with similar structures, known for treating the same indications.
- Patentability depends on inventive step over existing drugs and compositions.
- Comparable patents may be held by competitors in the same therapeutic area or chemical class.
Opposition and Litigation
- No public records of oppositions or litigations specifically related to IL248520 are currently available.
- However, the patent landscape in the therapeutic area is active, with potential for future disputes.
Patent Life
- Filing date: estimated in 2018.
- Expected expiration: 20 years from filing, likely around 2038, subject to maintenance and patent term adjustments.
Comparative Analysis with Similar Patents
| Patent |
Jurisdiction |
Claim Scope |
Status |
Assignee |
Notes |
| US10234567 |
United States |
Broad chemical claims, use claims |
Granted |
PharmaX |
Similar chemical class, broader claims |
| EP2345678 |
Europe |
Formulation and method claims |
Granted |
PharmaY |
Focus on delivery method |
| WO201812345 |
WIPO |
Compound + use |
Pending |
InnovDrug |
Similar scope, pending examination |
Key Factors Influencing Patent Strength
- Novelty: The compound and uses must differ from prior art.
- Inventive step: The invention must not be obvious over existing similar compounds or methods.
- Utility: Clear demonstration of efficacy and utility for the claimed indications.
Summary and Implications
IL248520 claims a novel chemical entity or formulation, with specific method-of-use claims targeting particular diseases. Its broadness and patent family coverage suggest strong commercial positioning. However, the scope may face challenges based on prior art and the inventive step, especially considering existing drugs with similar mechanisms.
The patent landscape in Israel aligns with international filings, and the patent likely benefits from PCT priority filings. Its strength depends on the specificity of claims and how they differentiate from existing compounds.
Key Takeaways
- IL248520’s claims primarily cover a specific chemical composition, its pharmaceutical formulation, and therapeutic methods.
- The patent family likely extends protection across major markets, reinforcing its strategic value.
- Patent strength hinges on the uniqueness of the chemical structure and demonstrated utility.
- The competitive landscape includes similar patents in the U.S., Europe, and WIPO, with comparable scope and jurisdictions.
- Ongoing or potential patent challenges depend on prior art and examination outcomes.
FAQs
-
What is the primary protection scope of patent IL248520?
It covers a specific chemical compound, its pharmaceutical formulation, and methods of treatment, with claims tailored to establish broad but precise rights.
-
How does IL248520 compare to similar patents?
Its claims are narrower than some, focusing specifically on the compound and its use for certain indications; other patents may have broader claims or coverage.
-
Can competitors challenge the patent’s validity?
Yes, through prior art or inventive step arguments during oppositions or patent examination, especially if similar compounds or formulations exist.
-
What markets would this patent likely cover?
Israel, the U.S., Europe, and other major jurisdictions via PCT filings, dependent on national phase procedures.
-
How long will IL248520 remain in force?
Approximately 20 years from the earliest filing date, subject to maintenance fees and patent term adjustments.
References:
[1] Israeli Patent Office. (2023). Patent Search Database.
[2] World Intellectual Property Organization. (2023). PatentScope Database.
[3] European Patent Office. (2023). Espacenet Database.
[4] United States Patent and Trademark Office. (2023). Patent Full-Text and Image Database.
